Grail shareholders filed a class action lawsuit in the U.S. District Court for the Northern District of California accusing Grail and executives of making false and misleading statements about the performance of its Galleri multi-cancer early detection test in the NHS-Galleri trial. The complaint targets CEO Bob Ragusa and others, alleging concealment of adverse facts after topline results from the first screening round. According to the filing, the company previously highlighted higher positive predictive value than the original Pathfinder study, and representatives allegedly reiterated favorable interpretations throughout earnings calls and conferences. The lawsuit points out that the trial later missed its primary endpoint of a statistically significant reduction in stage III and IV cancers. After the February announcement of the initial trial results, Grail’s stock reportedly dropped more than 50%, and the plaintiffs argue that earlier communications created a misleading impression about the likelihood of success.